1.1
Natalizumab (branded or biosimilar) is recommended as an option for the treatment only of rapidly evolving severe relapsing–remitting multiple sclerosis (RES‑RRMS) in adults. RES‑RRMS is defined by 2 or more relapses in the previous year, and baseline MRI evidence of disease activity.